Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
207679-81-0
Molecular formula
C22H31NO2
Molecular weight
341.5 g/mol
Drug class
Active metabolite of fesoterodinemuscarinic acetylcholine receptor antagonist
Mechanism of action
The active metabolite 5-hydroxymethyltolterodine competitively antagonises muscarinic receptors on bladder detrusor smooth muscle, reducing acetylcholine-mediated involuntary contractions and increasing functional bladder capacity.
Indications / reported uses
The clinically marketed prodrug fesoterodine is used for overactive bladder in adults and selected paediatric patients. Desfesoterodine is the active metabolite and is not usually marketed as an independent API; do not assign it a separate standalone indication.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Desfesoterodine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Desfesoterodine Permitted Daily Exposure (PDE) report (the Desfesoterodine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Desfesoterodine Occupational Exposure Limit (OEL) report (the Desfesoterodine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.